Literature DB >> 15557209

Combined smooth muscle and melanocytic differentiation in lymphangioleiomyomatosis.

Xiaoning Zhe1, Lucia Schuger.   

Abstract

Pulmonary lymphangioleiomyomatosis (LAM) is characterized by abnormal proliferation of immature-looking smooth muscle (SM)-like cells (LAM cells), leading to lung destruction and cyst formation. In addition to expressing some SM markers, scattered LAM cells express the melanocytic maker gp100, which is recognized by antibody HMB45, suggesting that at least a few LAM cells may have melanocytic differentiation. Here we immunostained 26 LAM samples for several melanocyte-related proteins. These studies showed that all LAM cells express tetraspanin CD63, a melanoma-associated protein that belongs to the transmembrane 4 superfamily. The majority of LAM cells also immunoreacted with PNL2, an antibody against a yet uncharacterized melanocytic antigen. Furthermore, we examined the co-expression of PNL2 and Ki-67, an indicator of cell proliferation, and found that PNL2-positive LAM cells showed a significantly lower proliferation rate compared with their negative counterparts. Our findings shed new light on the nature of the LAM cells by demonstrating their combined SM and melanocytic differentiation and the existence of subpopulations with different proliferative potential. Furthermore, these studies provided two new antibodies useful in the diagnosis of LAM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15557209     DOI: 10.1369/jhc.4A6438.2004

Source DB:  PubMed          Journal:  J Histochem Cytochem        ISSN: 0022-1554            Impact factor:   2.479


  24 in total

1.  Treatment option(s) for pulmonary lymphangioleiomyomatosis: progress and current challenges.

Authors:  Vera P Krymskaya
Journal:  Am J Respir Cell Mol Biol       Date:  2012-05       Impact factor: 6.914

Review 2.  The Lymphangioleiomyomatosis Lung Cell and Its Human Cell Models.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Thomas N Darling; Olga Torre; Sergio Harari; Joel Moss
Journal:  Am J Respir Cell Mol Biol       Date:  2018-06       Impact factor: 6.914

Review 3.  Feasibility of immunotherapy for lymphangioleiomyomatosis.

Authors:  Michele Carbone
Journal:  Am J Pathol       Date:  2009-11-05       Impact factor: 4.307

Review 4.  Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.

Authors:  Hen Prizant; Stephen R Hammes
Journal:  Endocrinology       Date:  2016-07-13       Impact factor: 4.736

5.  Human Pluripotent Stem Cell-Derived TSC2-Haploinsufficient Smooth Muscle Cells Recapitulate Features of Lymphangioleiomyomatosis.

Authors:  Lisa M Julian; Sean P Delaney; Ying Wang; Alexander A Goldberg; Carole Doré; Julien Yockell-Lelièvre; Roger Y Tam; Krinio Giannikou; Fiona McMurray; Molly S Shoichet; Mary-Ellen Harper; Elizabeth P Henske; David J Kwiatkowski; Thomas N Darling; Joel Moss; Arnold S Kristof; William L Stanford
Journal:  Cancer Res       Date:  2017-08-22       Impact factor: 12.701

Review 6.  Lymphangioleiomyomatosis: what do we know and what are we looking for?

Authors:  S Harari; O Torre; J Moss
Journal:  Eur Respir Rev       Date:  2011-03

Review 7.  Lymphangioleiomyomatosis and TSC2-/- cells.

Authors:  Thomas N Darling; Gustavo Pacheco-Rodriguez; Alfredo Gorio; Elena Lesma; Cheryl Walker; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

8.  In pulmonary lymphangioleiomyomatosis expression of progesterone receptor is frequently higher than that of estrogen receptor.

Authors:  Ling Gao; Michael M Yue; Jennifer Davis; Elisabeth Hyjek; Lucia Schuger
Journal:  Virchows Arch       Date:  2014-02-26       Impact factor: 4.064

Review 9.  Targeting the airway smooth muscle for asthma treatment.

Authors:  Blanca Camoretti-Mercado
Journal:  Transl Res       Date:  2009-07-14       Impact factor: 7.012

Review 10.  Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.

Authors:  Vera P Krymskaya
Journal:  Proc Am Thorac Soc       Date:  2008-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.